NCDActive
Intravenous Histamine Therapy
NCD21
Effective: January 1, 1966
Updated: December 31, 2025
Policy Summary
Intravenous histamine therapy is not covered by the program for any condition due to lack of scientifically valid evidence of therapeutic benefit; payments are not made for such therapy. Histamine has accepted uses only for diagnostic testing (gastric acid secretion, peripheral sensory nerve integrity, limb circulatory competency, and pheochromocytoma detection), not as a therapeutic agent.
Coverage Criteria Preview
Key requirements from the full policy
"Intravenous histamine therapy is not covered for any condition because there is no scientifically valid evidence of therapeutic effectiveness."
Sign up to see full coverage criteria, indications, and limitations.